U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890038) titled 'The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors' on Oct. 16.
Brief Summary: This project involves conducting integrated PET/MR or PET/CT imaging using a CAIX-targeted PET tracer (e.g., [68Ga]Ga-DOTA-CAIX peptide) in clinically diagnosed malignant tumor patients, aiming to achieve the following objectives:
Patients with malignant tumors: To visually assess the hypoxic state of malignant tumors, with pathological immunohistochemical detection of CAIX expression levels as the gold standard, evaluate the detection efficacy and quantitative accuracy of CAIX PET imaging for tumor hypoxic regions; c...